铂-话题@MedSci

#铂#

382篇内容 | 6023人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1737754, encodeId=5d591e37754e5, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, objectTitle=ESMO Open：紫杉醇联合卡铂的一线方案加用贝伐珠单抗治疗复发性/转移性鼻咽癌, objectType=article, longId=221315, objectId=ce4a22131527, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ce4a22131527, replyNumber=0, likeNumber=119, createdTime=2022-10-01, rootId=0, userName=ms3153534357578991, userId=ca4034296500, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ce4a22131527, moduleTitle=ESMO Open：紫杉醇联合卡铂的一线方案加用贝伐珠单抗治疗复发性/转移性鼻咽癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ce4a22131527)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1737708, encodeId=a1771e377082c, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, objectTitle=Ann Oncol：纳武利尤单抗（Nivolumab）联合卡铂、紫杉醇和贝伐珠单抗一线治疗晚期非鳞状非小细胞肺癌的疗效和安全性, objectType=article, longId=213326, objectId=17162133260e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=17162133260e, replyNumber=0, likeNumber=73, createdTime=2022-06-05, rootId=0, userName=ms3153534357578991, userId=ca4034296500, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=17162133260e, moduleTitle=Ann Oncol：纳武利尤单抗（Nivolumab）联合卡铂、紫杉醇和贝伐珠单抗一线治疗晚期非鳞状非小细胞肺癌的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=17162133260e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1737720, encodeId=dc251e3772039, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, objectTitle=JTO:信迪利单抗（Sintilimab）联合培美曲塞+铂类一线治疗局部进展或转移性非鳞状非小细胞肺癌的OS结果更新： 3期临床研究（ORIENT-11）。, objectType=article, longId=215469, objectId=aafc2154691d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=aafc2154691d, replyNumber=0, likeNumber=82, createdTime=2022-06-15, rootId=0, userName=ms3153534357578991, userId=ca4034296500, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aafc2154691d, moduleTitle=JTO:信迪利单抗（Sintilimab）联合培美曲塞+铂类一线治疗局部进展或转移性非鳞状非小细胞肺癌的OS结果更新： 3期临床研究（ORIENT-11）。, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=aafc2154691d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1737744, encodeId=93d41e3774440, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, objectTitle=吉西他滨与奥沙利铂联合对复发、耐药老年淋巴瘤患者的疗效与安全性分析, objectType=article, longId=220684, objectId=5d632206847f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5d632206847f, replyNumber=0, likeNumber=54, createdTime=2022-04-29, rootId=0, userName=ms3153534357578991, userId=ca4034296500, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5d632206847f, moduleTitle=吉西他滨与奥沙利铂联合对复发、耐药老年淋巴瘤患者的疗效与安全性分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5d632206847f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1737767, encodeId=5def1e377678c, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, objectTitle=J Clin Oncol：三阴性乳腺癌新辅助化疗加入卡铂或贝伐珠单抗并不能改善患者的长期预后（LTOs）, objectType=article, longId=294716, objectId=db94294e16ed, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=db94294e16ed, replyNumber=0, likeNumber=68, createdTime=2022-12-13, rootId=0, userName=ms3153534357578991, userId=ca4034296500, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=db94294e16ed, moduleTitle=J Clin Oncol：三阴性乳腺癌新辅助化疗加入卡铂或贝伐珠单抗并不能改善患者的长期预后（LTOs）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=db94294e16ed)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1737731, encodeId=a2b81e377313d, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, objectTitle=Front Oncol：贝伐单抗或帕博利珠单抗联合培美曲塞+铂类化疗一线治疗驱动基因阴性晚期非鳞非小细胞肺癌(NSCLC)的直接疗效对比, objectType=article, longId=217997, objectId=faae21e997e8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=faae21e997e8, replyNumber=0, likeNumber=81, createdTime=2022-01-23, rootId=0, userName=ms3153534357578991, userId=ca4034296500, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=faae21e997e8, moduleTitle=Front Oncol：贝伐单抗或帕博利珠单抗联合培美曲塞+铂类化疗一线治疗驱动基因阴性晚期非鳞非小细胞肺癌(NSCLC)的直接疗效对比, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=faae21e997e8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1737735, encodeId=b7d41e377351f, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, objectTitle=Int J Urol：铂基一线化疗对转移性尿路上皮癌患者总生存的影响, objectType=article, longId=219077, objectId=4bf12190e736, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4bf12190e736, replyNumber=0, likeNumber=130, createdTime=2021-12-06, rootId=0, userName=ms3153534357578991, userId=ca4034296500, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4bf12190e736, moduleTitle=Int J Urol：铂基一线化疗对转移性尿路上皮癌患者总生存的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4bf12190e736)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1737689, encodeId=941e1e3768987, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, objectTitle=Lancet Oncol：中山大学肿瘤医院郭翔教授团队通过3期试验证实第三代铂类药物洛铂可有效治疗局部晚期鼻咽癌！, objectType=article, longId=210300, objectId=c2092103002f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c2092103002f, replyNumber=0, likeNumber=85, createdTime=2022-03-31, rootId=0, userName=ms3153534357578991, userId=ca4034296500, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c2092103002f, moduleTitle=Lancet Oncol：中山大学肿瘤医院郭翔教授团队通过3期试验证实第三代铂类药物洛铂可有效治疗局部晚期鼻咽癌！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c2092103002f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1737696, encodeId=1d641e3769657, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, objectTitle=JAMA Oncology：降低奥沙利铂/卡培他滨化疗强度对老年或体弱晚期胃食管癌患者的生活质量和疗效评估：来自GO2 III期随机临床试验结果, objectType=article, longId=211614, objectId=6cbb211614a4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6cbb211614a4, replyNumber=0, likeNumber=64, createdTime=2022-05-02, rootId=0, userName=ms3153534357578991, userId=ca4034296500, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6cbb211614a4, moduleTitle=JAMA Oncology：降低奥沙利铂/卡培他滨化疗强度对老年或体弱晚期胃食管癌患者的生活质量和疗效评估：来自GO2 III期随机临床试验结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6cbb211614a4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1737723, encodeId=428f1e3772314, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, objectTitle=Clin Cancer Res：PI3K/mTORC1/2双重抑制剂Gedatolisib联合卡铂和紫杉醇治疗晚期实体肿瘤, objectType=article, longId=215909, objectId=bd1421590942, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bd1421590942, replyNumber=0, likeNumber=65, createdTime=2022-02-02, rootId=0, userName=ms3153534357578991, userId=ca4034296500, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bd1421590942, moduleTitle=Clin Cancer Res：PI3K/mTORC1/2双重抑制剂Gedatolisib联合卡铂和紫杉醇治疗晚期实体肿瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bd1421590942)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1737715, encodeId=96261e37715d8, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, objectTitle=J Clin Oncol: Amivantamab治疗铂类进展的EGFR 20外显子插入突变非小细胞肺癌的安全性和疗效：I期研究CHRYSALIS的初次分析结果, objectType=article, longId=215256, objectId=71942152560f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=71942152560f, replyNumber=0, likeNumber=71, createdTime=2021-11-16, rootId=0, userName=ms3153534357578991, userId=ca4034296500, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=71942152560f, moduleTitle=J Clin Oncol: Amivantamab治疗铂类进展的EGFR 20外显子插入突变非小细胞肺癌的安全性和疗效：I期研究CHRYSALIS的初次分析结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=71942152560f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1737750, encodeId=942b1e377503c, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, objectTitle=晚期胃癌患者外周血ERCC1基因多态性与奥沙利铂疗效相关性的研究, objectType=article, longId=221042, objectId=3d7022104236, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3d7022104236, replyNumber=0, likeNumber=63, createdTime=2022-01-13, rootId=0, userName=ms3153534357578991, userId=ca4034296500, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3d7022104236, moduleTitle=晚期胃癌患者外周血ERCC1基因多态性与奥沙利铂疗效相关性的研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3d7022104236)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1737780, encodeId=34bd1e3778041, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, objectTitle=Oncologist：Toripalimab（特瑞普利单抗）联合紫杉醇+卡铂新辅助治疗可切除局部晚期食管鳞状细胞癌的疗效, objectType=article, longId=299451, objectId=fc31299451e9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fc31299451e9, replyNumber=0, likeNumber=99, createdTime=2022-07-18, rootId=0, userName=ms3153534357578991, userId=ca4034296500, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fc31299451e9, moduleTitle=Oncologist：Toripalimab（特瑞普利单抗）联合紫杉醇+卡铂新辅助治疗可切除局部晚期食管鳞状细胞癌的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fc31299451e9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1737742, encodeId=71d51e377429e, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, objectTitle=Nat Med：PD-L1抑制剂durvalumab联合铂类+培美曲塞治疗既往未治、不能切除的恶性胸膜间皮瘤(MPM)的疗效和安全性：II期临床研究PrE0505, objectType=article, longId=220461, objectId=b29d2204611e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b29d2204611e, replyNumber=0, likeNumber=48, createdTime=2021-12-16, rootId=0, userName=ms3153534357578991, userId=ca4034296500, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b29d2204611e, moduleTitle=Nat Med：PD-L1抑制剂durvalumab联合铂类+培美曲塞治疗既往未治、不能切除的恶性胸膜间皮瘤(MPM)的疗效和安全性：II期临床研究PrE0505, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b29d2204611e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1737776, encodeId=9eec1e3777664, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, objectTitle=Lancet Oncol：纳武单抗联合奥沙利铂化疗一线治疗晚期或复发性胃或胃食管交界癌, objectType=article, longId=295669, objectId=d4cf2956690e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d4cf2956690e, replyNumber=0, likeNumber=57, createdTime=2022-05-31, rootId=0, userName=ms3153534357578991, userId=ca4034296500, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d4cf2956690e, moduleTitle=Lancet Oncol：纳武单抗联合奥沙利铂化疗一线治疗晚期或复发性胃或胃食管交界癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d4cf2956690e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1737753, encodeId=fda41e377536c, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, objectTitle=重组人血管内皮抑制素联合顺铂治疗乳腺癌恶性胸腔积液疗效观察, objectType=article, longId=221296, objectId=527022129651, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=527022129651, replyNumber=0, likeNumber=51, createdTime=2022-10-06, rootId=0, userName=ms3153534357578991, userId=ca4034296500, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=527022129651, moduleTitle=重组人血管内皮抑制素联合顺铂治疗乳腺癌恶性胸腔积液疗效观察, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=527022129651)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1737700, encodeId=47b31e377009b, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, objectTitle=Br J Cancer：Berzosertib联合顺铂治疗晚期实体瘤患者的临床研究, objectType=article, longId=212381, objectId=7eea212381eb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7eea212381eb, replyNumber=0, likeNumber=70, createdTime=2021-11-28, rootId=0, userName=ms3153534357578991, userId=ca4034296500, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7eea212381eb, moduleTitle=Br J Cancer：Berzosertib联合顺铂治疗晚期实体瘤患者的临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7eea212381eb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1737722, encodeId=84911e3772267, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, objectTitle=J Clin Oncol：吉西他滨联合顺铂较氟尿嘧啶联合顺铂改善复发性或转移性鼻咽癌患者的预后: III期研究GEM20110714最终OS分析, objectType=article, longId=215670, objectId=64082156e056, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=64082156e056, replyNumber=0, likeNumber=60, createdTime=2021-10-07, rootId=0, userName=ms3153534357578991, userId=ca4034296500, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=64082156e056, moduleTitle=J Clin Oncol：吉西他滨联合顺铂较氟尿嘧啶联合顺铂改善复发性或转移性鼻咽癌患者的预后: III期研究GEM20110714最终OS分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=64082156e056)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1737714, encodeId=c1a11e3771414, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, objectTitle=Br J Cancer：阿司匹林增强顺铂治疗食管鳞癌的疗效, objectType=article, longId=215172, objectId=d9d42151e26a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d9d42151e26a, replyNumber=0, likeNumber=63, createdTime=2021-10-26, rootId=0, userName=ms3153534357578991, userId=ca4034296500, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d9d42151e26a, moduleTitle=Br J Cancer：阿司匹林增强顺铂治疗食管鳞癌的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d9d42151e26a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1737768, encodeId=1e501e37768be, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, objectTitle=PD-L1高表达（90%）的晚期NSCLC免疫+含铂双药化疗效果不好是什么原因？下一步治疗方法是什么？, objectType=article, longId=294782, objectId=5533294e8241, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5533294e8241, replyNumber=0, likeNumber=57, createdTime=2022-05-29, rootId=0, userName=ms3153534357578991, userId=ca4034296500, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5533294e8241, moduleTitle=PD-L1高表达（90%）的晚期NSCLC免疫+含铂双药化疗效果不好是什么原因？下一步治疗方法是什么？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5533294e8241)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

铂

2020-05-29

ms3153534357578991 (审核中...)

前往app查看评论内容

#铂#

ESMO Open：紫杉醇联合卡铂的一线方案加用贝伐珠单抗治疗复发性/转移性鼻咽癌

2022-10-01

ms3153534357578991 (审核中...)

前往app查看评论内容

#铂#

Ann Oncol：纳武利尤单抗（Nivolumab）联合卡铂、紫杉醇和贝伐珠单抗一线治疗晚期非鳞状非小细胞肺癌的疗效和安全性

2022-06-05

ms3153534357578991 (审核中...)

前往app查看评论内容

#铂#

JTO:信迪利单抗（Sintilimab）联合培美曲塞+铂类一线治疗局部进展或转移性非鳞状非小细胞肺癌的OS结果更新： 3期临床研究（ORIENT-11）。

2022-06-15

ms3153534357578991 (审核中...)

前往app查看评论内容

#铂#

吉西他滨与奥沙利铂联合对复发、耐药老年淋巴瘤患者的疗效与安全性分析

2022-04-29

ms3153534357578991 (审核中...)

前往app查看评论内容

#铂#

J Clin Oncol：三阴性乳腺癌新辅助化疗加入卡铂或贝伐珠单抗并不能改善患者的长期预后（LTOs）

2022-12-13

ms3153534357578991 (审核中...)

前往app查看评论内容

#铂#

Front Oncol：贝伐单抗或帕博利珠单抗联合培美曲塞+铂类化疗一线治疗驱动基因阴性晚期非鳞非小细胞肺癌(NSCLC)的直接疗效对比

2022-01-23

ms3153534357578991 (审核中...)

前往app查看评论内容

#铂#

Int J Urol：铂基一线化疗对转移性尿路上皮癌患者总生存的影响

2021-12-06

ms3153534357578991 (审核中...)

前往app查看评论内容

#铂#

Lancet Oncol：中山大学肿瘤医院郭翔教授团队通过3期试验证实第三代铂类药物洛铂可有效治疗局部晚期鼻咽癌！

2022-03-31

ms3153534357578991 (审核中...)

前往app查看评论内容

#铂#

JAMA Oncology：降低奥沙利铂/卡培他滨化疗强度对老年或体弱晚期胃食管癌患者的生活质量和疗效评估：来自GO2 III期随机临床试验结果

2022-05-02

ms3153534357578991 (审核中...)

前往app查看评论内容

#铂#

Clin Cancer Res：PI3K/mTORC1/2双重抑制剂Gedatolisib联合卡铂和紫杉醇治疗晚期实体肿瘤

2022-02-02

ms3153534357578991 (审核中...)

前往app查看评论内容

#铂#

J Clin Oncol: Amivantamab治疗铂类进展的EGFR 20外显子插入突变非小细胞肺癌的安全性和疗效：I期研究CHRYSALIS的初次分析结果

2021-11-16

ms3153534357578991 (审核中...)

前往app查看评论内容

#铂#

晚期胃癌患者外周血ERCC1基因多态性与奥沙利铂疗效相关性的研究

2022-01-13

ms3153534357578991 (审核中...)

前往app查看评论内容

#铂#

Oncologist：Toripalimab（特瑞普利单抗）联合紫杉醇+卡铂新辅助治疗可切除局部晚期食管鳞状细胞癌的疗效

2022-07-18

ms3153534357578991 (审核中...)

前往app查看评论内容

#铂#

Nat Med：PD-L1抑制剂durvalumab联合铂类+培美曲塞治疗既往未治、不能切除的恶性胸膜间皮瘤(MPM)的疗效和安全性：II期临床研究PrE0505

2021-12-16

ms3153534357578991 (审核中...)

前往app查看评论内容

#铂#

Lancet Oncol：纳武单抗联合奥沙利铂化疗一线治疗晚期或复发性胃或胃食管交界癌

2022-05-31

ms3153534357578991 (审核中...)

前往app查看评论内容

#铂#

重组人血管内皮抑制素联合顺铂治疗乳腺癌恶性胸腔积液疗效观察

2022-10-06

ms3153534357578991 (审核中...)

前往app查看评论内容

#铂#

Br J Cancer：Berzosertib联合顺铂治疗晚期实体瘤患者的临床研究

2021-11-28

ms3153534357578991 (审核中...)

前往app查看评论内容

#铂#

J Clin Oncol：吉西他滨联合顺铂较氟尿嘧啶联合顺铂改善复发性或转移性鼻咽癌患者的预后: III期研究GEM20110714最终OS分析

2021-10-07

ms3153534357578991 (审核中...)

前往app查看评论内容

#铂#

Br J Cancer：阿司匹林增强顺铂治疗食管鳞癌的疗效

2021-10-26

ms3153534357578991 (审核中...)

前往app查看评论内容

#铂#

PD-L1高表达（90%）的晚期NSCLC免疫+含铂双药化疗效果不好是什么原因？下一步治疗方法是什么？

2022-05-29

科室
- - 订阅+
  - 更多科室
工具
服务